Abstract
Background Several diagnostic biomarkers are currently available for its clinical use in early onset cognitive impairment. The decision of which biomarker is used in each patient depends on several factors such as its predictive value or tolerability. Methods Forty subjects with early onset cognitive complaints ( p p<0.05). Biomarkers results led to diagnostic (32.5%) and treatment (32.5%) changes. All tests were well tolerated. Conclusions Biomarkers procedures are well tolerated and they have an important diagnostic/ therapeutic impact on the early onset cognitive impairment.
Funding Information
  • Generalitat de Catalunya (PERIS SLT002/16/00329, SLT002/16/00408)
  • Instituto de Salud Carlos III (PI14/00282)

This publication has 23 references indexed in Scilit: